Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ceapro, a Canada-based biotechnology company, has entered into a material transfer agreement (MTA) with the National Research Council of Canada (NRC) to evaluate a new series of active ingredients from a variety of rosehips native to Prince Edward Island.
Subscribe to our email newsletter
Ceapro said previous collaborative work by the University of Prince Edward Island, NRC, and Agriculture and Agri-Food Canada found that a specific variety contained multiple compounds are capable of providing therapeutic benefits.
Synergistic studies combining active ingredients from the rosehips and Ceapro’s active ingredients have already begun at the NRC and awaits for preliminary results.
Ceapro has the option to negotiate a license to commercialize some or all elements of the NRC’s intellectual property, as part of the MTA.
Ceapro CSO David Fielder said they have already seen a potentiation of the efficacy of a prescribed drug up to four times when combined with one of their active ingredients.
As part of this collaboration, Innovation PEI has provided a non repayable grant funding of up to $100,000 through its Development and Commercialization Fund.